Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Nov 1;88(21):9448-52.
doi: 10.1073/pnas.88.21.9448.

Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides

M K Hart  1 , K J Weinhold, R M Scearce, E M Washburn, C A Clark, T J Palker, B F Haynes
Affiliations

Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides

M K Hart et al. Proc Natl Acad Sci U S A. .

Abstract

The generation of antiviral cytotoxic T lymphocytes (CTLs) is a critical component of the immune response to viral infections. A safe and nontoxic vaccine for AIDS would optimally use a carrier-free synthetic peptide immunogen containing only components of HIV necessary for induction of protective immune responses. We report that hybrid synthetic peptides containing either a HIV envelope gp120 T-cell determinant (T1) or the envelope gp41 fusion domain (F) N-terminal to HIV CTL determinants are capable of priming murine CD8+, major histocompatibility complex class I-restricted anti-HIV CTLs in vivo. These data demonstrate that carrier-free, nonderivatized synthetic peptides can be used in vivo to induce anti-HIV CTL responses.

PubMed Disclaimer

References

    1. J Immunol. 1985 Mar;134(3):1999-2003 - PubMed
    1. Cell. 1988 Aug 12;54(4):561-75 - PubMed
    1. Eur J Immunol. 1987 Feb;17(2):269-73 - PubMed
    1. Nature. 1987 Jun 11-17;327(6122):473-6 - PubMed
    1. Proc Natl Acad Sci U S A. 1987 Jun;84(12):4249-53 - PubMed

Publication types